Page last updated: 2024-12-11

ethyl fumarate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5358902
CHEMBL ID1771637
SCHEMBL ID60569
SCHEMBL ID141140
MeSH IDM0169698

Synonyms (51)

Synonym
LS-13140
BB 0216624
monoethyl fumarate
ethyl hydrogen fumarate
fumaric acid, monoethyl ester
ethyl fumarate
2459-05-4
2-butenedioic acid (e)-, monoethyl ester
(2e)-4-ethoxy-4-oxobut-2-enoic acid
STK367237
nsc-244252
nsc244252
mono-ethyl fumarate, 95%
AKOS000118854
4-ethoxy-4-oxobut-2-enoic acid
(e)-4-ethoxy-4-oxobut-2-enoic acid
F0359
fumaric acid monoethyl ester
CHEMBL1771637 ,
(e)-4-ethoxy-4-oxo-2-butenoic acid
mono-ethyl fumarate
NCGC00255854-01
tox21_301978
cas-3249-53-4
dtxcid9024485
3249-53-4
bdbm50342427
monoethyl trans-2-butenedioate
einecs 219-544-7
nsc 524101
fumaric acid, ethyl ester
y3w849ng2n ,
unii-y3w849ng2n
ethyl fumarate [who-dd]
SCHEMBL60569
SCHEMBL141140
fumaric acid mono-ethyl ester
(2e)-4-ethoxy-4-oxo-2-butenoic acid #
W-107299
mono-ethyl fumarate, certified reference material, tracecert(r)
ethylhydrogenfumarat
CS-0030808
AS-12529
2-butenedioic acid (2e)-, 1-ethyl ester
Q27294232
A937009
EN300-364770
HY-W019696
DTXSID701021503
EN300-19541
Z2315575179

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events in were noted in 62% of the patients (mainly flushing and gastrointestinal complaints)."( [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].
Altmeyer, P; Hartwig, R; Matthes, U, 1996
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" Moreover, in whole blood the half-life of DMF was dramatically reduced as compared to serum."( In vitro pharmacokinetics of anti-psoriatic fumaric acid esters.
Litjens, NH; Mattie, H; Nibbering, PH; Thio, HB; van Dissel, JT; van Gulpen, C; van Strijen, E, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Dosage of FAE was performed according to the standard therapy regimen for psoriasis patients."( Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters.
Altmeyer, P; Gambichler, T; Hanefeld, C; Kastner, U; Nowack, U, 2002
)
0.31
" Dosage of FAE was given according to the standard therapy regimen for psoriasis."( Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study.
Altmeyer, P; Gambichler, T; Knierim, C; Kreuter, A; Pawlak, F; Rotterdam, S; Stücker, M, 2005
)
0.33
" While the clinical efficacy of this FAE mixture is well established, the combination of esters on which it is based, and its dosing regimen, was determined empirically."( Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Amasuno, A; Asadullah, K; Landeck, L; Mrowietz, U; Pau-Charles, I, 2018
)
1.1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency48.55770.006038.004119,952.5996AID1159521
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency49.17870.001022.650876.6163AID1224838; AID1224839; AID1224893
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.54120.000229.305416,493.5996AID743075
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency10.07500.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydroxycarboxylic acid receptor 2Homo sapiens (human)Ki0.41000.00401.49308.1000AID594381
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
negative regulation of lipid catabolic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of adiponectin secretionHydroxycarboxylic acid receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
nicotinic acid receptor activityHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
cell junctionHydroxycarboxylic acid receptor 2Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1432751Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432755Competitive inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production preincubated with enzyme followed by addition of varying levels of urea as substrate measured for 120 mins by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432759Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring initial state enzyme-inhibitor complex using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432760Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring steady state enzyme-inhibitor complex using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432756Reversible inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring recovery of enzyme activity at 10 times IC50 preincubated for 60 mins followed by 100-fold dilution in to PBS containing urea as subst2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432754Time-dependent Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production using urea as substrate by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID594381Displacement of [3H]nicotinic acid from human GPR109a receptor expressed in human HEK293T cells by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.63)18.7374
1990's17 (44.74)18.2507
2000's9 (23.68)29.6817
2010's9 (23.68)24.3611
2020's2 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.49 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index5.81 (4.65)
Search Engine Demand Index30.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (15.79%)5.53%
Reviews1 (2.63%)6.00%
Case Studies4 (10.53%)4.05%
Observational1 (2.63%)0.25%
Other26 (68.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]